Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Myelofibrosis (PMF)”

67 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 67 results

Early research (Phase 1)Study completedNCT01317875
What this trial is testing

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Who this might be right for
Myelofibrosis
Incyte Corporation 69
Testing effectiveness (Phase 2)UnknownNCT01298934
What this trial is testing

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Who this might be right for
Primary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis
Ronald Hoffman 22
Testing effectiveness (Phase 2)Study completedNCT02515630
What this trial is testing

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV) MyelofibrosisPostessential Thrombocythemia (Post-ET) Myelofibrosis
Sierra Oncology LLC - a GSK company 41
Early research (Phase 1)Looking for participantsNCT05279001
What this trial is testing

A Safety and Tolerability Study of Jaktinib

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT03441113
What this trial is testing

Extended Access of Momelotinib in Adults With Myelofibrosis

Who this might be right for
NeoplasmsPost-polycythemia Vera Myelofibrosis (Post-PV MF)Primary Myelofibrosis (PMF)+1 more
GlaxoSmithKline 237
Testing effectiveness (Phase 2)Study completedNCT04217993
What this trial is testing

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis(Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 51
Testing effectiveness (Phase 2)WithdrawnNCT04629651
What this trial is testing

Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

Who this might be right for
Bone Marrow FibrosisMyeloproliferative Neoplasm
Case Comprehensive Cancer Center
Early research (Phase 1)Ended earlyNCT03373877
What this trial is testing

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more
Samus Therapeutics, Inc. 4
Testing effectiveness (Phase 2)Study completedNCT00935987
What this trial is testing

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Sierra Oncology LLC - a GSK company 166
Large-scale testing (Phase 3)UnknownNCT03662126
What this trial is testing

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF)
Kartos Therapeutics, Inc. 385
Testing effectiveness (Phase 2)Study completedNCT01633372
What this trial is testing

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 87
Early research (Phase 1)Ended earlyNCT04637009
What this trial is testing

TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Who this might be right for
Acute Myeloid LeukemiaMyeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm
Astex Pharmaceuticals, Inc. 20
Large-scale testing (Phase 3)Study completedNCT02101268
What this trial is testing

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Sierra Oncology LLC - a GSK company 156
Early research (Phase 1)Study completedNCT02493530
What this trial is testing

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Who this might be right for
MyelofibrosisPolycythemia Vera
Vanderbilt-Ingram Cancer Center 60
Testing effectiveness (Phase 2)Study completedNCT03136185
What this trial is testing

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Who this might be right for
MyelofibrosisPost-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)+1 more
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) 90
Testing effectiveness (Phase 2)WithdrawnNCT04054245
What this trial is testing

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Myelofibrosis Transformation in Essential ThrombocythemiaPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary Myelofibrosis
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02966353
What this trial is testing

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera-MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals 51
Not applicableUnknownNCT03116542
What this trial is testing

18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia

Who this might be right for
Essential ThrombocythemiaPrimary Myelofibrosis, Fibrotic StagePrimary Myelofibrosis, Prefibrotic Stage
Hamad Medical Corporation 21
Early research (Phase 1)Ended earlyNCT01730248
What this trial is testing

Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 63
Testing effectiveness (Phase 2)Ended earlyNCT01758588
What this trial is testing

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Who this might be right for
Myelofibrosis
Weill Medical College of Cornell University 8
Load More Results